Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 8
---
, 
    2025  
    For the 
    Period from 
    February 14, 
    2024 through 
    June 30, 
    2024  
    For the 
    Period from 
    January 1, 
    2024 through 
    February 13, 
    2024 

    (Successor)  
    (Successor)  
    (Predecessor) 

    Cash flows from operating activities: 

    Net loss 
    $(10,523,246) 
    $(4,176,137) 
    $(572,211)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Gain from settlement of liabilities with vendors 
     -  
     (589,223) 
     - 
  
    Depreciation expense 
     145,715  
     190,591  
     37,356 
  
    Stock-based compensation 
     488,274  
     1,485,027  
     4,431 
  
    Amortization of right-to-use operating lease asset 
     391,417  
     237,607  
     115,859 
  
    Stock-based inducement expense 
     863,550  
     -  
     - 
  
    Amortization of debt discount 
     -  
     -  
     (1,875)
  
    Gain on revaluation of earnout and derivative liabilities 
     -  
     (4,700,000) 
     (320,117)
  
    Change in assets and liabilities: 

    Prepaid expenses and other current assets 
     (169,143) 
     (411,224) 
     142,687 
  
    Accounts payable 
     561,901  
     (679,551) 
     128,429 
  
    Accrued liabilities 
     (404,289) 
     991,399  
     (50,370)
  
    Operating lease liability 
     (422,881) 
     (328,374) 
     (121,589)
  
    Net cash used in operating activities 
     (9,068,702) 
     (7,979,885) 
     (637,400)